Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Immune checkpoint inhibitor (ICI)-induced colitis is one of the known complications of therapies targeting cytotoxic programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death ligand 1 (PD-L1). ICI-associated colitis is routinely treated w...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Leilei Fang, Changqin Liu, Xiaomin Sun, Zhanju Liu
Natura:	Articolo
Lingua:	English
Pubblicazione:	Frontiers Media S.A. 2022-06-01
Serie:	Frontiers in Oncology
Soggetti:	anti-tumor necrosis factor-α colitis durvalumab immune checkpoint inhibitor programmed cell death ligand 1 vedolizumab
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2022.925964/full

Documenti analoghi

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
di: Hamzah Abu-Sbeih, et al.
Pubblicazione: (2018-12-01)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
di: Hamzah Abu-Sbeih, et al.
Pubblicazione: (2019-04-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
di: Sae Ohwada, et al.
Pubblicazione: (2022-06-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
di: Eva Zhang, et al.
Pubblicazione: (2021-05-01)

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases
di: Ocepek Andreja
Pubblicazione: (2024-03-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
di: Ayaka Kaneoka, et al.
Pubblicazione: (2022-02-01)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
di: Xiaolin Liu, et al.
Pubblicazione: (2020-12-01)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
di: Manuel Morgado, et al.
Pubblicazione: (2020-10-01)

A real-world study of vedolizumab versus infliximab in patients with moderate to severe ulcerative colitis
di: MENG Ruiping, et al.
Pubblicazione: (2024-06-01)

Gut microbiome and checkpoint inhibitor colitis
di: Kanika Sehgal, et al.
Pubblicazione: (2021-10-01)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
di: Takafumi Yorozuya, et al.
Pubblicazione: (2020-04-01)

Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab
di: Shion Kachi, et al.
Pubblicazione: (2024-05-01)

Checkpoint Inhibitor-Induced Colitis: An Update
di: Giuseppe Losurdo, et al.
Pubblicazione: (2023-05-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
di: Fateen Ata, et al.
Pubblicazione: (2024-12-01)

Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
di: Kei Nomura, et al.
Pubblicazione: (2024-09-01)

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
di: Michael V. Chiorean, et al.
Pubblicazione: (2022-04-01)

Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
di: Qian Li, et al.
Pubblicazione: (2024-06-01)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
di: Dart RJ, et al.
Pubblicazione: (2017-03-01)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
di: Ting Zhou, et al.
Pubblicazione: (2021-08-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
di: Carmen Portenkirchner, et al.
Pubblicazione: (2021-04-01)

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
di: J. Rotman, et al.
Pubblicazione: (2018-09-01)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
di: Sergio Di Molfetta, et al.
Pubblicazione: (2021-04-01)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
di: Aaron G. Issac, et al.
Pubblicazione: (2022-06-01)

Leishmania donovani infection mimicking ulcerative colitis in an immuno-competent patient
di: Jonas Buttenschoen, et al.
Pubblicazione: (2024-10-01)

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
di: Petkau JM, et al.
Pubblicazione: (2016-03-01)

The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces
di: Raffaele Pellegrino, et al.
Pubblicazione: (2024-11-01)

Development of shellfish allergy after exposure to dual immune checkpoint blockade
di: Zachary J Brown, et al.
Pubblicazione: (2018-01-01)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
di: Hamzah Abu-Sbeih, et al.
Pubblicazione: (2018-09-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
di: Jeong Yeon Kim, et al.
Pubblicazione: (2020-03-01)

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy
di: Roberto Ravasio, et al.
Pubblicazione: (2023-01-01)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
di: Guanzhou Zhou, et al.
Pubblicazione: (2022-10-01)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
di: Laurent Peyrin‐Biroulet, et al.
Pubblicazione: (2024-03-01)

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
di: Chia-Jung Kuo, et al.
Pubblicazione: (2022-09-01)

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
di: Masayuki Ueno, et al.
Pubblicazione: (2022-09-01)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
di: Harm Westdorp, et al.
Pubblicazione: (2021-10-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
di: Keiichi Haga, et al.
Pubblicazione: (2022-10-01)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
di: Yinghong Wang, et al.
Pubblicazione: (2018-05-01)

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1
di: Loftus EV Jr, et al.
Pubblicazione: (2020-06-01)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
di: Anastasiya A. Glibka, et al.
Pubblicazione: (2022-10-01)

Characteristics and clinical outcomes of checkpoint inhibitor-associated pneumonia in cancer patients: a retrospective analysis of 1 084 cases
di: YANG Yan, et al.
Pubblicazione: (2024-08-01)